Systems for and Methods of Hybrid Pyrosequencing
The systems and methods of the invention provide a guided approach to pyrosequencing (i.e., hybrid pyrosequencing). A de novo nucleic acid sequence may compared to a library of possible results and the next nucleotide to be dispensed is selected based on the comparison of the de novo sequence and the library of possible results. In another example, at least the first nucleotide to be dispensed is selected based on a query of a database(s) of non-sequence parameters (e.g., incidence of infection, diagnostic symptoms, sample source) and subsequent dispensations determined based on a comparison of the de novo sequence and the library of possible results (e.g., candidate sequences). The systems and methods of the invention may be performed using a droplet actuator.
Latest ADVANCED LIQUID LOGIC, INC. Patents:
- Methods of improving accuracy and precision of droplet metering using an on-actuator reservoir as the fluid input
- Manipulation of beads in droplets and methods for manipulating droplets
- Bead incubation and washing on a droplet actuator
- Methods of improving accuracy and precision of droplet metering using an on-actuator reservoir as the fluid input
- Droplet-based surface modification and washing
This application claims the benefit of U.S. provisional application No. 61/504,796 filed Jul. 6, 2011, the disclosure of which is hereby incorporated by reference in its entirety.
GOVERNMENT INTERESTThis invention was made with government support under HG004354 awarded by the National Institute of Health. The government has certain rights in the invention.
TECHNICAL FIELDThe present disclosure relates to methods for pyrosequencing.
BACKGROUNDA droplet actuator typically includes one or more substrates configured to form a surface or gap for conducting droplet operations. The one or more substrates establish a droplet operations surface or gap for conducting droplet operations and may also include electrodes arranged to conduct the droplet operations. The droplet operations substrate or the gap between the substrates may be coated or filled with a filler fluid that is immiscible with the liquid that forms the droplets.
Droplet actuators are used to conduct a variety of molecular protocols, such as amplification of nucleic acids and nucleic acid sequencing. Nucleic acid amplification and sequencing methods are used in a wide variety of settings, such as medical diagnostics and detection of sequence variations. Pyrosequencing is a sequencing-by-synthesis method in which a primed DNA template strand is sequentially exposed to one of four nucleotides in the presence of DNA polymerase. The nucleotides are sequentially added one by one according to a fixed order dependent on the template and pre-determined by the user. Consequently, the operator must enter the order of the nucleotides before the instrument analysis begins. Thus, the operator needs to know the sequence of the sample in order to be able to enter the dispensation order in advance. In certain instances, an optimal dispensation order may be difficult to determine or is not known. As a consequence, many unnecessary dispensations may be made where no nucleotides are incorporated. Unnecessary dispensations are a waste of time and resources and contribute to a decline in accuracy as the sequencing reaction progresses. Recent advances in pyrosequencing technology include methods for using sequence information in a database of alleles and adapting the dispensation order in real-time during the analysis. However, this approach is limited to statistical selection of the next nucleotide to add based only on nucleotide frequency in a database. Therefore, there is a need for improved pyrosequencing methods for rapid, accurate and efficient sequencing of nucleic acids.
DEFINITIONSAs used herein, the following terms have the meanings indicated.
“Activate,” with reference to one or more electrodes, means affecting a change in the electrical state of the one or more electrodes which, in the presence of a droplet, results in a droplet operation. Activation of an electrode can be accomplished using alternating or direct current. Any suitable voltage may be used. For example, an electrode may be activated using a voltage which is greater than about 150 V, or greater than about 200 V, or greater than about 250 V, or from about 275 V to about 375 V, or about 300 V. Where alternating current is used, any suitable frequency may be employed. For example, an electrode may be activated using alternating current having a frequency from about 1 Hz to about 100 Hz, or from about 10 Hz to about 60 Hz, or from about 20 Hz to about 40 Hz, or about 30 Hz.
“Bead,” with respect to beads on a droplet actuator, means any bead or particle that is capable of interacting with a droplet on or in proximity with a droplet actuator. Beads may be any of a wide variety of shapes, such as spherical, generally spherical, egg shaped, disc shaped, cubical, amorphous and other three dimensional shapes. The bead may, for example, be capable of being subjected to a droplet operation in a droplet on a droplet actuator or otherwise configured with respect to a droplet actuator in a manner which permits a droplet on the droplet actuator to be brought into contact with the bead on the droplet actuator and/or off the droplet actuator. Beads may be provided in a droplet, in a droplet operations gap, or on a droplet operations surface. Beads may be provided in a reservoir that is external to a droplet operations gap or situated apart from a droplet operations surface, and the reservoir may be associated with a fluid path that permits a droplet including the beads to be brought into a droplet operations gap or into contact with a droplet operations surface. Beads may be manufactured using a wide variety of materials, including for example, resins, and polymers. The beads may be any suitable size, including for example, microbeads, microparticles, nanobeads and nanoparticles. In some cases, beads are magnetically responsive; in other cases beads are not significantly magnetically responsive. For magnetically responsive beads, the magnetically responsive material may constitute substantially all of a bead, a portion of a bead, or only one component of a bead. The remainder of the bead may include, among other things, polymeric material, coatings, and moieties which permit attachment of an assay reagent. Examples of suitable beads include flow cytometry microbeads, polystyrene microparticles and nanoparticles, functionalized polystyrene microparticles and nanoparticles, coated polystyrene microparticles and nanoparticles, silica microbeads, fluorescent microspheres and nanospheres, functionalized fluorescent microspheres and nanospheres, coated fluorescent microspheres and nanospheres, color dyed microparticles and nanoparticles, magnetic microparticles and nanoparticles, superparamagnetic microparticles and nanoparticles (e.g., DYNABEADS® particles, available from Invitrogen Group, Carlsbad, Calif.), fluorescent microparticles and nanoparticles, coated magnetic microparticles and nanoparticles, ferromagnetic microparticles and nanoparticles, coated ferromagnetic microparticles and nanoparticles, and those described in U.S. Patent Publication Nos. 20050260686, entitled “Multiplex flow assays preferably with magnetic particles as solid phase,” published on Nov. 24, 2005; 20030132538, entitled “Encapsulation of discrete quanta of fluorescent particles,” published on Jul. 17, 2003; 20050118574, entitled “Multiplexed Analysis of Clinical Specimens Apparatus and Method,” published on Jun. 2, 2005; 20050277197. Entitled “Microparticles with Multiple Fluorescent Signals and Methods of Using Same,” published on Dec. 15, 2005; 20060159962, entitled “Magnetic Microspheres for use in Fluorescence-based Applications,” published on Jul. 20, 2006; the entire disclosures of which are incorporated herein by reference for their teaching concerning beads and magnetically responsive materials and beads. Beads may be pre-coupled with a biomolecule or other substance that is able to bind to and form a complex with a biomolecule. Beads may be pre-coupled with an antibody, protein or antigen, DNA/RNA probe or any other molecule with an affinity for a desired target. Examples of droplet actuator techniques for immobilizing magnetically responsive beads and/or non-magnetically responsive beads and/or conducting droplet operations protocols using beads are described in U.S. patent application Ser. No. 11/639,566, entitled “Droplet-Based Particle Sorting,” filed on Dec. 15, 2006; U.S. Patent Application No. 61/039,183, entitled “Multiplexing Bead Detection in a Single Droplet,” filed on Mar. 25, 2008; U.S. Patent Application No. 61/047,789, entitled “Droplet Actuator Devices and Droplet Operations Using Beads,” filed on Apr. 25, 2008; U.S. Patent Application No. 61/086,183, entitled “Droplet Actuator Devices and Methods for Manipulating Beads,” filed on Aug. 5, 2008; International Patent Application No. PCT/US2008/053545, entitled “Droplet Actuator Devices and Methods Employing Magnetic Beads,” filed on Feb. 11, 2008; International Patent Application No. PCT/US2008/058018, entitled “Bead-based Multiplexed Analytical Methods and Instrumentation,” filed on Mar. 24, 2008; International Patent Application No. PCT/US2008/058047, “Bead Sorting on a Droplet Actuator,” filed on Mar. 23, 2008; and International Patent Application No. PCT/US2006/047486, entitled “Droplet-based Biochemistry,” filed on Dec. 11, 2006; the entire disclosures of which are incorporated herein by reference. Bead characteristics may be employed in the multiplexing aspects of the invention. Examples of beads having characteristics suitable for multiplexing, as well as methods of detecting and analyzing signals emitted from such beads, may be found in U.S. Patent Publication No. 20080305481, entitled “Systems and Methods for Multiplex Analysis of PCR in Real Time,” published on Dec. 11, 2008; U.S. Patent Publication No. 20080151240, “Methods and Systems for Dynamic Range Expansion,” published on Jun. 26, 2008; U.S. Patent Publication No. 20070207513, entitled “Methods, Products, and Kits for Identifying an Analyte in a Sample,” published on Sep. 6, 2007; U.S. Patent Publication No. 20070064990, entitled “Methods and Systems for Image Data Processing,” published on Mar. 22, 2007; U.S. Patent Publication No. 20060159962, entitled “Magnetic Microspheres for use in Fluorescence-based Applications,” published on Jul. 20, 2006; U.S. Patent Publication No. 20050277197, entitled “Microparticles with Multiple Fluorescent Signals and Methods of Using Same,” published on Dec. 15, 2005; and U.S. Patent Publication No. 20050118574, entitled “Multiplexed Analysis of Clinical Specimens Apparatus and Method,” published on Jun. 2, 2005.
“Droplet” means a volume of liquid on a droplet actuator. Typically, a droplet is at least partially bounded by a filler fluid. For example, a droplet may be completely surrounded by a filler fluid or may be bounded by filler fluid and one or more surfaces of the droplet actuator. As another example, a droplet may be bounded by filler fluid, one or more surfaces of the droplet actuator, and/or the atmosphere. As yet another example, a droplet may be bounded by filler fluid and the atmosphere. Droplets may, for example, be aqueous or non-aqueous or may be mixtures or emulsions including aqueous and non-aqueous components. Droplets may take a wide variety of shapes; nonlimiting examples include generally disc shaped, slug shaped, truncated sphere, ellipsoid, spherical, partially compressed sphere, hemispherical, ovoid, cylindrical, combinations of such shapes, and various shapes formed during droplet operations, such as merging or splitting or formed as a result of contact of such shapes with one or more surfaces of a droplet actuator. For examples of droplet fluids that may be subjected to droplet operations using the approach of the invention, see International Patent Application No. PCT/US 06/47486, entitled, “Droplet-Based Biochemistry,” filed on Dec. 11, 2006. In various embodiments, a droplet may include a biological sample, such as whole blood, lymphatic fluid, serum, plasma, sweat, tear, saliva, sputum, cerebrospinal fluid, amniotic fluid, seminal fluid, vaginal excretion, serous fluid, synovial fluid, pericardial fluid, peritoneal fluid, pleural fluid, transudates, exudates, cystic fluid, bile, urine, gastric fluid, intestinal fluid, fecal samples, liquids containing single or multiple cells, liquids containing organelles, fluidized tissues, fluidized organisms, liquids containing multi-celled organisms, biological swabs and biological washes. Moreover, a droplet may include a reagent, such as water, deionized water, saline solutions, acidic solutions, basic solutions, detergent solutions and/or buffers. Other examples of droplet contents include reagents, such as a reagent for a biochemical protocol, such as a nucleic acid amplification protocol, an affinity-based assay protocol, an enzymatic assay protocol, a sequencing protocol, and/or a protocol for analyses of biological fluids.
“Droplet Actuator” means a device for manipulating droplets. For examples of droplet actuators, see Pamula et al., U.S. Pat. No. 6,911,132, entitled “Apparatus for Manipulating Droplets by Electrowetting-Based Techniques,” issued on Jun. 28, 2005; Pamula et al., U.S. patent application Ser. No. 11/343,284, entitled “Apparatuses and Methods for Manipulating Droplets on a Printed Circuit Board,” filed on filed on Jan. 30, 2006; Pollack et al., International Patent Application No. PCT/US2006/047486, entitled “Droplet-Based Biochemistry,” filed on Dec. 11, 2006; Shenderov, U.S. Pat. No. 6,773,566, entitled “Electrostatic Actuators for Microfluidics and Methods for Using Same,” issued on Aug. 10, 2004 and U.S. Pat. No. 6,565,727, entitled “Actuators for Microfluidics Without Moving Parts,” issued on Jan. 24, 2000; Kim and/or Shah et al., U.S. patent application Ser. No. 10/343,261, entitled “Electrowetting-driven Micropumping,” filed on Jan. 27, 2003, Ser. No. 11/275,668, entitled “Method and Apparatus for Promoting the Complete Transfer of Liquid Drops from a Nozzle,” filed on Jan. 23, 2006, Ser. No. 11/460,188, entitled “Small Object Moving on Printed Circuit Board,” filed on Jan. 23, 2006, Ser. No. 12/465,935, entitled “Method for Using Magnetic Particles in Droplet Microfluidics,” filed on May 14, 2009, and Ser. No. 12/513,157, entitled “Method and Apparatus for Real-time Feedback Control of Electrical Manipulation of Droplets on Chip,” filed on Apr. 30, 2009; Velev, U.S. Pat. No. 7,547,380, entitled “Droplet Transportation Devices and Methods Having a Fluid Surface,” issued on Jun. 16, 2009; Sterling et al., U.S. Pat. No. 7,163,612, entitled “Method, Apparatus and Article for Microfluidic Control via Electrowetting, for Chemical, Biochemical and Biological Assays and the Like,” issued on Jan. 16, 2007; Becker and Gascoyne et al., U.S. Pat. No. 7,641,779, entitled “Method and Apparatus for Programmable fluidic Processing,” issued on Jan. 5, 2010, and U.S. Pat. No. 6,977,033, entitled “Method and Apparatus for Programmable fluidic Processing,” issued on Dec. 20, 2005; Decre et al., U.S. Pat. No. 7,328,979, entitled “System for Manipulation of a Body of Fluid,” issued on Feb. 12, 2008; Yamakawa et al., U.S. Patent Pub. No. 20060039823, entitled “Chemical Analysis Apparatus,” published on Feb. 23, 2006; Wu, International Patent Pub. No. WO/2009/003184, entitled “Digital Microfluidics Based Apparatus for Heat-exchanging Chemical Processes,” published on Dec. 31, 2008; Fouillet et al., U.S. Patent Pub. No. 20090192044, entitled “Electrode Addressing Method,” published on Jul. 30, 2009; Fouillet et al., U.S. Pat. No. 7,052,244, entitled “Device for Displacement of Small Liquid Volumes Along a Micro-catenary Line by Electrostatic Forces,” issued on May 30, 2006; Marchand et al., U.S. Patent Pub. No. 20080124252, entitled “Droplet Microreactor,” published on May 29, 2008; Adachi et al., U.S. Patent Pub. No. 20090321262, entitled “Liquid Transfer Device,” published on Dec. 31, 2009; Roux et al., U.S. Patent Pub. No. 20050179746, entitled “Device for Controlling the Displacement of a Drop Between two or Several Solid Substrates,” published on Aug. 18, 2005; Dhindsa et al., “Virtual Electrowetting Channels Electronic Liquid Transport with Continuous Channel Functionality,” Lab Chip, 10:832-836 (2010); the entire disclosures of which are incorporated herein by reference, along with their priority documents. Certain droplet actuators will include one or more substrates arranged with a gap therebetween and electrodes associated with (e.g., layered on, attached to, and/or embedded in) the one or more substrates and arranged to conduct one or more droplet operations. For example, certain droplet actuators will include a base (or bottom) substrate, droplet operations electrodes associated with the substrate, one or more dielectric layers atop the substrate and/or electrodes, and optionally one or more hydrophobic layers atop the substrate, dielectric layers and/or the electrodes forming a droplet operations surface. A top substrate may also be provided, which is separated from the droplet operations surface by a gap, commonly referred to as a droplet operations gap. Various electrode arrangements on the top and/or bottom substrates are discussed in the above-referenced patents and applications and certain novel electrode arrangements are discussed in the description of the invention. During droplet operations it is preferred that droplets remain in continuous contact or frequent contact with a ground or reference electrode. A ground or reference electrode may be associated with the top substrate facing the gap, the bottom substrate facing the gap, in the gap. Where electrodes are provided on both substrates, electrical contacts for coupling the electrodes to a droplet actuator instrument for controlling or monitoring the electrodes may be associated with one or both plates. In some cases, electrodes on one substrate are electrically coupled to the other substrate so that only one substrate is in contact with the droplet actuator. In one embodiment, a conductive material (e.g., an epoxy, such as MASTER BOND™ Polymer System EP79, available from Master Bond, Inc., Hackensack, N.J.) provides the electrical connection between electrodes on one substrate and electrical paths on the other substrates, e.g., a ground electrode on a top substrate may be coupled to an electrical path on a bottom substrate by such a conductive material. Where multiple substrates are used, a spacer may be provided between the substrates to determine the height of the gap therebetween and define dispensing reservoirs. The spacer height may, for example, be from about 5 μm to about 600 μm, or about 100 μm to about 400 μm, or about 200 μm to about 350 μm, or about 250 μm to about 300 μm, or about 275 μm. The spacer may, for example, be formed of a layer of projections form the top or bottom substrates, and/or a material inserted between the top and bottom substrates. One or more openings may be provided in the one or more substrates for forming a fluid path through which liquid may be delivered into the droplet operations gap. The one or more openings may in some cases be aligned for interaction with one or more electrodes, e.g., aligned such that liquid flowed through the opening will come into sufficient proximity with one or more droplet operations electrodes to permit a droplet operation to be effected by the droplet operations electrodes using the liquid. The base (or bottom) and top substrates may in some cases be formed as one integral component. One or more reference electrodes may be provided on the base (or bottom) and/or top substrates and/or in the gap. Examples of reference electrode arrangements are provided in the above referenced patents and patent applications. In various embodiments, the manipulation of droplets by a droplet actuator may be electrode mediated, e.g., electrowetting mediated or dielectrophoresis mediated or Coulombic force mediated. Examples of other techniques for controlling droplet operations that may be used in the droplet actuators of the invention include using devices that induce hydrodynamic fluidic pressure, such as those that operate on the basis of mechanical principles (e.g. external syringe pumps, pneumatic membrane pumps, vibrating membrane pumps, vacuum devices, centrifugal forces, piezoelectric/ultrasonic pumps and acoustic forces); electrical or magnetic principles (e.g. electroosmotic flow, electrokinetic pumps, ferrofluidic plugs, electrohydrodynamic pumps, attraction or repulsion using magnetic forces and magnetohydrodynamic pumps); thermodynamic principles (e.g. gas bubble generation/phase-change-induced volume expansion); other kinds of surface-wetting principles (e.g. electrowetting, and optoelectrowetting, as well as chemically, thermally, structurally and radioactively induced surface-tension gradients); gravity; surface tension (e.g., capillary action); electrostatic forces (e.g., electroosmotic flow); centrifugal flow (substrate disposed on a compact disc and rotated); magnetic forces (e.g., oscillating ions causes flow); magnetohydrodynamic forces; and vacuum or pressure differential. In certain embodiments, combinations of two or more of the foregoing techniques may be employed to conduct a droplet operation in a droplet actuator of the invention. Similarly, one or more of the foregoing may be used to deliver liquid into a droplet operations gap, e.g., from a reservoir in another device or from an external reservoir of the droplet actuator (e.g., a reservoir associated with a droplet actuator substrate and a fluid path from the reservoir into the droplet operations gap). Droplet operations surfaces of certain droplet actuators of the invention may be made from hydrophobic materials or may be coated or treated to make them hydrophobic. For example, in some cases some portion or all of the droplet operations surfaces may be derivatized with low surface-energy materials or chemistries, e.g., by deposition or using in situ synthesis using compounds such as poly- or per-fluorinated compounds in solution or polymerizable monomers. Examples include TEFLON® AF (available from DuPont, Wilmington, Del.), members of the cytop family of materials, coatings in the FLUOROPEL® family of hydrophobic and superhydrophobic coatings (available from Cytonix Corporation, Beltsville, Md.), silane coatings, fluorosilane coatings, hydrophobic phosphonate derivatives (e.g., those sold by Aculon, Inc), and NOVEC™ electronic coatings (available from 3M Company, St. Paul, Minn.), and other fluorinated monomers for plasma-enhanced chemical vapor deposition (PECVD). In some cases, the droplet operations surface may include a hydrophobic coating having a thickness ranging from about 10 nm to about 1,000 nm. Moreover, in some embodiments, the top substrate of the droplet actuator includes an electrically conducting organic polymer, which is then coated with a hydrophobic coating or otherwise treated to make the droplet operations surface hydrophobic. For example, the electrically conducting organic polymer that is deposited onto a plastic substrate may be poly(3,4-ethylenedioxythiophene) poly(styrenesulfonate) (PEDOT:PSS). Other examples of electrically conducting organic polymers and alternative conductive layers are described in Pollack et al., International Patent Application No. PCT/US2010/040705, entitled “Droplet Actuator Devices and Methods,” the entire disclosure of which is incorporated herein by reference. One or both substrates may be fabricated using a printed circuit board (PCB), glass, indium tin oxide (ITO)-coated glass, and/or semiconductor materials as the substrate. When the substrate is ITO-coated glass, the ITO coating is preferably a thickness in the range of about 20 to about 200 nm, preferably about 50 to about 150 nm, or about 75 to about 125 nm, or about 100 nm. In some cases, the top and/or bottom substrate includes a PCB substrate that is coated with a dielectric, such as a polyimide dielectric, which may in some cases also be coated or otherwise treated to make the droplet operations surface hydrophobic. When the substrate includes a PCB, the following materials are examples of suitable materials: MITSUI™ BN-300 (available from MITSUI Chemicals America, Inc., San Jose Calif.); ARLON™ 11N (available from Arlon, Inc, Santa Ana, Calif.); NELCO® N4000-6 and N5000-30/32 (available from Park Electrochemical Corp., Melville, N.Y.); ISOLA™ FR406 (available from Isola Group, Chandler, Ariz.), especially IS620; fluoropolymer family (suitable for fluorescence detection since it has low background fluorescence); polyimide family; polyester; polyethylene naphthalate; polycarbonate; polyetheretherketone; liquid crystal polymer; cyclo-olefin copolymer (COC); cyclo-olefin polymer (COP); aramid; THERMOUNT® nonwoven aramid reinforcement (available from DuPont, Wilmington, Del.); NOMEX® brand fiber (available from DuPont, Wilmington, Del.); and paper. Various materials are also suitable for use as the dielectric component of the substrate. Examples include: vapor deposited dielectric, such as PARYLENE™ C (especially on glass) and PARYLENE™ N (available from Parylene Coating Services, Inc., Katy, Tex.); TEFLON® AF coatings; cytop; soldermasks, such as liquid photoimageable soldermasks (e.g., on PCB) like TAIYO™ PSR4000 series, TAIYO™ PSR and AUS series (available from Taiyo America, Inc. Carson City, Nev.) (good thermal characteristics for applications involving thermal control), and PROBIMER™ 8165 (good thermal characteristics for applications involving thermal control (available from Huntsman Advanced Materials Americas Inc., Los Angeles, Calif.); dry film soldermask, such as those in the VACREL® dry film soldermask line (available from DuPont, Wilmington, Del.); film dielectrics, such as polyimide film (e.g., KAPTON® polyimide film, available from DuPont, Wilmington, Del.), polyethylene, and fluoropolymers (e.g., FEP), polytetrafluoroethylene; polyester; polyethylene naphthalate; cyclo-olefin copolymer (COC); cyclo-olefin polymer (COP); any other PCB substrate material listed above; black matrix resin; and polypropylene. Droplet transport voltage and frequency may be selected for performance with reagents used in specific assay protocols. Design parameters may be varied, e.g., number and placement of on-actuator reservoirs, number of independent electrode connections, size (volume) of different reservoirs, placement of magnets/bead washing zones, electrode size, inter-electrode pitch, and gap height (between top and bottom substrates) may be varied for use with specific reagents, protocols, droplet volumes, etc. In some cases, a substrate of the invention may derivatized with low surface-energy materials or chemistries, e.g., using deposition or in situ synthesis using poly- or per-fluorinated compounds in solution or polymerizable monomers. Examples include TEFLON® AF coatings and FLUOROPEL® coatings for dip or spray coating, and other fluorinated monomers for plasma-enhanced chemical vapor deposition (PECVD). Additionally, in some cases, some portion or all of the droplet operations surface may be coated with a substance for reducing background noise, such as background fluorescence from a PCB substrate. For example, the noise-reducing coating may include a black matrix resin, such as the black matrix resins available from Toray industries, Inc., Japan. Electrodes of a droplet actuator are typically controlled by a controller or a processor, which is itself provided as part of a system, which may include processing functions as well as data and software storage and input and output capabilities. Reagents may be provided on the droplet actuator in the droplet operations gap or in a reservoir fluidly coupled to the droplet operations gap. The reagents may be in liquid form, e.g., droplets, or they may be provided in a reconstitutable form in the droplet operations gap or in a reservoir fluidly coupled to the droplet operations gap. Reconstitutable reagents may typically be combined with liquids for reconstitution. An example of reconstitutable reagents suitable for use with the invention includes those described in Meathrel, et al., U.S. Pat. No. 7,727,466, entitled “Disintegratable films for diagnostic devices,” granted on Jun. 1, 2010.
“Droplet operation” means any manipulation of a droplet on a droplet actuator. A droplet operation may, for example, include: loading a droplet into the droplet actuator; dispensing one or more droplets from a source droplet; splitting, separating or dividing a droplet into two or more droplets; transporting a droplet from one location to another in any direction; merging or combining two or more droplets into a single droplet; diluting a droplet; mixing a droplet; agitating a droplet; deforming a droplet; retaining a droplet in position; incubating a droplet; heating a droplet; vaporizing a droplet; cooling a droplet; disposing of a droplet; transporting a droplet out of a droplet actuator; other droplet operations described herein; and/or any combination of the foregoing. The terms “merge,” “merging,” “combine,” “combining” and the like are used to describe the creation of one droplet from two or more droplets. It should be understood that when such a term is used in reference to two or more droplets, any combination of droplet operations that are sufficient to result in the combination of the two or more droplets into one droplet may be used. For example, “merging droplet A with droplet B,” can be achieved by transporting droplet A into contact with a stationary droplet B, transporting droplet B into contact with a stationary droplet A, or transporting droplets A and B into contact with each other. The terms “splitting,” “separating” and “dividing” are not intended to imply any particular outcome with respect to volume of the resulting droplets (i.e., the volume of the resulting droplets can be the same or different) or number of resulting droplets (the number of resulting droplets may be 2, 3, 4, 5 or more). The term “mixing” refers to droplet operations which result in more homogenous distribution of one or more components within a droplet. Examples of “loading” droplet operations include microdialysis loading, pressure assisted loading, robotic loading, passive loading, and pipette loading. Droplet operations may be electrode-mediated. In some cases, droplet operations are further facilitated by the use of hydrophilic and/or hydrophobic regions on surfaces and/or by physical obstacles. For examples of droplet operations, see the patents and patent applications cited above under the definition of “droplet actuator.” Impedance or capacitance sensing or imaging techniques may sometimes be used to determine or confirm the outcome of a droplet operation. Examples of such techniques are described in Sturmer et al., International Patent Pub. No. WO/2008/101194, entitled “Capacitance Detection in a Droplet Actuator,” published on Aug. 21, 2008, the entire disclosure of which is incorporated herein by reference. Generally speaking, the sensing or imaging techniques may be used to confirm the presence or absence of a droplet at a specific electrode. For example, the presence of a dispensed droplet at the destination electrode following a droplet dispensing operation confirms that the droplet dispensing operation was effective. Similarly, the presence of a droplet at a detection spot at an appropriate step in an assay protocol may confirm that a previous set of droplet operations has successfully produced a droplet for detection. Droplet transport time can be quite fast. For example, in various embodiments, transport of a droplet from one electrode to the next may exceed about 1 sec, or about 0.1 sec, or about 0.01 sec, or about 0.001 sec. In one embodiment, the electrode is operated in AC mode but is switched to DC mode for imaging. It is helpful for conducting droplet operations for the footprint area of droplet to be similar to electrowetting area; in other words, 1×-, 2×-3×-droplets are usefully controlled operated using 1, 2, and 3 electrodes, respectively. If the droplet footprint is greater than the number of electrodes available for conducting a droplet operation at a given time, the difference between the droplet size and the number of electrodes should typically not be greater than 1; in other words, a 2× droplet is usefully controlled using 1 electrode and a 3× droplet is usefully controlled using 2 electrodes. When droplets include beads, it is useful for droplet size to be equal to the number of electrodes controlling the droplet, e.g., transporting the droplet.
“Filler fluid” means a fluid associated with a droplet operations substrate of a droplet actuator, which fluid is sufficiently immiscible with a droplet phase to render the droplet phase subject to electrode-mediated droplet operations. For example, the gap of a droplet actuator is typically filled with a filler fluid. The filler fluid may, for example, be a low-viscosity oil, such as silicone oil or hexadecane filler fluid. The filler fluid may fill the entire gap of the droplet actuator or may coat one or more surfaces of the droplet actuator. Filler fluids may be conductive or non-conductive. Filler fluids may, for example, be doped with surfactants or other additives. For example, additives may be selected to improve droplet operations and/or reduce loss of reagent or target substances from droplets, formation of microdroplets, cross contamination between droplets, contamination of droplet actuator surfaces, degradation of droplet actuator materials, etc. Composition of the filler fluid, including surfactant doping, may be selected for performance with reagents used in the specific assay protocols and effective interaction or non-interaction with droplet actuator materials. Examples of filler fluids and filler fluid formulations suitable for use with the invention are provided in Srinivasan et al, International Patent Pub. Nos. WO/2010/027894, entitled “Droplet Actuators, Modified Fluids and Methods,” published on Mar. 11, 2010, and WO/2009/021173, entitled “Use of Additives for Enhancing Droplet Operations,” published on Feb. 12, 2009; Sista et al., International Patent Pub. No. WO/2008/098236, entitled “Droplet Actuator Devices and Methods Employing Magnetic Beads,” published on Aug. 14, 2008; and Monroe et al., U.S. Patent Publication No. 20080283414, entitled “Electrowetting Devices,” filed on May 17, 2007; the entire disclosures of which are incorporated herein by reference, as well as the other patents and patent applications cited herein.
“Immobilize” with respect to magnetically responsive beads, means that the beads are substantially restrained in position in a droplet or in filler fluid on a droplet actuator. For example, in one embodiment, immobilized beads are sufficiently restrained in position in a droplet to permit execution of a droplet splitting operation, yielding one droplet with substantially all of the beads and one droplet substantially lacking in the beads.
“Magnetically responsive” means responsive to a magnetic field. “Magnetically responsive beads” include or are composed of magnetically responsive materials. Examples of magnetically responsive materials include paramagnetic materials, ferromagnetic materials, ferrimagnetic materials, and metamagnetic materials. Examples of suitable paramagnetic materials include iron, nickel, and cobalt, as well as metal oxides, such as Fe3O4, BaFe12O19, CoO, NiO, Mn2O3, Cr2O3, and CoMnP.
“Reservoir” means an enclosure or partial enclosure configured for holding, storing, or supplying liquid. A droplet actuator system of the invention may include on-cartridge reservoirs and/or off-cartridge reservoirs. On-cartridge reservoirs may be (1) on-actuator reservoirs, which are reservoirs in the droplet operations gap or on the droplet operations surface; (2) off-actuator reservoirs, which are reservoirs on the droplet actuator cartridge, but outside the droplet operations gap, and not in contact with the droplet operations surface; or (3) hybrid reservoirs which have on-actuator regions and off-actuator regions. An example of an off-actuator reservoir is a reservoir in the top substrate. An off-actuator reservoir is typically in fluid communication with an opening or fluid path arranged for flowing liquid from the off-actuator reservoir into the droplet operations gap, such as into an on-actuator reservoir. An off-cartridge reservoir may be a reservoir that is not part of the droplet actuator cartridge at all, but which flows liquid to some portion of the droplet actuator cartridge. For example, an off-cartridge reservoir may be part of a system or docking station to which the droplet actuator cartridge is coupled during operation. Similarly, an off-cartridge reservoir may be a reagent storage container or syringe which is used to force fluid into an on-cartridge reservoir or into a droplet operations gap. A system using an off-cartridge reservoir will typically include a fluid passage means whereby liquid may be transferred from the off-cartridge reservoir into an on-cartridge reservoir or into a droplet operations gap.
“Transporting into the magnetic field of a magnet,” “transporting towards a magnet,” and the like, as used herein to refer to droplets and/or magnetically responsive beads within droplets, is intended to refer to transporting into a region of a magnetic field capable of substantially attracting magnetically responsive beads in the droplet. Similarly, “transporting away from a magnet or magnetic field,” “transporting out of the magnetic field of a magnet,” and the like, as used herein to refer to droplets and/or magnetically responsive beads within droplets, is intended to refer to transporting away from a region of a magnetic field capable of substantially attracting magnetically responsive beads in the droplet, whether or not the droplet or magnetically responsive beads is completely removed from the magnetic field. It will be appreciated that in any of such cases described herein, the droplet may be transported towards or away from the desired region of the magnetic field, and/or the desired region of the magnetic field may be moved towards or away from the droplet. Reference to an electrode, a droplet, or magnetically responsive beads being “within” or “in” a magnetic field, or the like, is intended to describe a situation in which the electrode is situated in a manner which permits the electrode to transport a droplet into and/or away from a desired region of a magnetic field, or the droplet or magnetically responsive beads is/are situated in a desired region of the magnetic field, in each case where the magnetic field in the desired region is capable of substantially attracting any magnetically responsive beads in the droplet. Similarly, reference to an electrode, a droplet, or magnetically responsive beads being “outside of” or “away from” a magnetic field, and the like, is intended to describe a situation in which the electrode is situated in a manner which permits the electrode to transport a droplet away from a certain region of a magnetic field, or the droplet or magnetically responsive beads is/are situated away from a certain region of the magnetic field, in each case where the magnetic field in such region is not capable of substantially attracting any magnetically responsive beads in the droplet or in which any remaining attraction does not eliminate the effectiveness of droplet operations conducted in the region. In various aspects of the invention, a system, a droplet actuator, or another component of a system may include a magnet, such as one or more permanent magnets (e.g., a single cylindrical or bar magnet or an array of such magnets, such as a Halbach array) or an electromagnet or array of electromagnets, to form a magnetic field for interacting with magnetically responsive beads or other components on chip. Such interactions may, for example, include substantially immobilizing or restraining movement or flow of magnetically responsive beads during storage or in a droplet during a droplet operation or pulling magnetically responsive beads out of a droplet.
“Washing” with respect to washing a bead means reducing the amount and/or concentration of one or more substances in contact with the bead or exposed to the bead from a droplet in contact with the bead. The reduction in the amount and/or concentration of the substance may be partial, substantially complete, or even complete. The substance may be any of a wide variety of substances; examples include target substances for further analysis, and unwanted substances, such as components of a sample, contaminants, and/or excess reagent. In some embodiments, a washing operation begins with a starting droplet in contact with a magnetically responsive bead, where the droplet includes an initial amount and initial concentration of a substance. The washing operation may proceed using a variety of droplet operations. The washing operation may yield a droplet including the magnetically responsive bead, where the droplet has a total amount and/or concentration of the substance which is less than the initial amount and/or concentration of the substance. Examples of suitable washing techniques are described in Pamula et al., U.S. Pat. No. 7,439,014, entitled “Droplet-Based Surface Modification and Washing,” granted on Oct. 21, 2008, the entire disclosure of which is incorporated herein by reference.
The terms “top,” “bottom,” “over,” “under,” and “on” are used throughout the description with reference to the relative positions of components of the droplet actuator, such as relative positions of top and bottom substrates of the droplet actuator. It will be appreciated that the droplet actuator is functional regardless of its orientation in space.
When a liquid in any form (e.g., a droplet or a continuous body, whether moving or stationary) is described as being “on”, “at”, or “over” an electrode, array, matrix or surface, such liquid could be either in direct contact with the electrode/array/matrix/surface, or could be in contact with one or more layers or films that are interposed between the liquid and the electrode/array/matrix/surface.
When a droplet is described as being “on” or “loaded on” a droplet actuator, it should be understood that the droplet is arranged on the droplet actuator in a manner which facilitates using the droplet actuator to conduct one or more droplet operations on the droplet, the droplet is arranged on the droplet actuator in a manner which facilitates sensing of a property of or a signal from the droplet, and/or the droplet has been subjected to a droplet operation on the droplet actuator.
The invention provides systems and methods for varying the dispensation order of nucleotides in a pyrosequencing reaction depending on the specific sample being analyzed. In one embodiment, the methods of the invention use a guided approach to pyrosequencing (i.e., hybrid pyrosequencing) in which a de novo sequence is compared to a database(s) of possible results and the next nucleotide to be dispensed is selected based the most probable base for that position. The database of possible results may include predetermined possible candidate sequences and non-sequence parameters, such as organism type and incidence of infection, diagnostic symptoms, and/or sample source. In another embodiment, the methods of the invention use a combination of pyrosequencing protocols, e.g., de novo sequencing, directed pyrosequencing, and hybrid pyrosequencing, to rapidly and efficiently determine target nucleic acid sequences in a sample being analyzed.
The systems and methods of the invention may be used to rapidly and efficiently identify one or more organisms in a sample. The sample may, for example, be a biological sample or an environmental sample. In one example, the systems and methods of the invention may be used to identify and type clinically relevant microorganisms such as bacteria, viruses and fungi. In another example, the systems and methods of the invention may be used to rule out known organisms and determine the sequence of an unknown organism(s) in a sample.
The methods of the invention are applicable to a variety of pyrosequencing platforms. In one embodiment, the system and methods of the invention are used in droplet-based pyrosequencing on a droplet actuator.
Hybrid PyrosequencingThe systems and methods of the invention provide a guided approach to pyrosequencing (i.e., hybrid pyrosequencing). In various embodiments, a de novo nucleic acid sequence is compared to a library of possible results and the next nucleotide to be dispensed is selected based on the comparison of the de novo sequence and the library of possible results. In one embodiment, at least the first nucleotide to be dispensed is selected based on a query of a database(s) of non-sequence parameters (e.g., incidence of infection, diagnostic symptoms, sample source) and subsequent dispensations determined based on a comparison of the de novo sequence and the library of possible results (e.g., candidate sequences).
Pyrosequencing is a sequencing-by-synthesis method in which a primed DNA template strand is sequentially exposed to one of four deoxynucleotide triphosphates (dNTPs) in the presence of DNA polymerase. If the added nucleotide is complementary to the next unpaired base, then it is incorporated by the polymerase and inorganic pyrophosphate (PPi) is released. Real-time detection of PPi occurs through an enzymatic cascade in which PPi is converted by a second enzyme, sulfurylase, to ATP which provides energy for a third enzyme, luciferase, to oxidize luciferin and generate a light signal. The amount of light generated is proportional to the number of adjacent unpaired bases complementary to the added nucleotide. In some pyrosequencing protocols, a fourth enzyme, apyrase, is used to degrade the excess dNTP and ATPs prior to the next reaction cycle, i.e., another nucleotide addition. Nucleotide incorporation proceeds sequentially along each template as each nucleotide is made available. In one example, each nucleotide may be made available in a preselected or programmed order. In another example, each nucleotide may be made available in a dynamic order, i.e., a continuously changing order.
The methods of hybrid pyrosequencing of the invention include detecting a measurable signal produced by a reaction when a nucleotide is incorporated into a de novo nucleic acid sequence, registering and storing the detected nucleic acid sequence, comparing the detected sequence to a retrievable (searchable) library of possible results, and adapting the order of following nucleotide dispensations in response to the comparison of the detected and registered sequence and the library of possible results. A library of possible results may include, but is not limited to, a database of a plurality of candidate sequences that is likely to include the detected and registered nucleic acid sequence; a database of incidence of infection and organism type; and a database of diagnostic symptoms and organism type. In various embodiments, the methods of the invention uses a combination of selection (separation) algorithms to query a library of possible results and adapt the order of nucleotide dispensation in response to a measurable signal produced by a reaction when a nucleotide is incorporated into a de novo sequence. Each time a nucleotide is dispensed, the nucleotide is either incorporated or not. Based on the returned information signal, certain candidate sequences in the library that do not match the de novo sequence can be eliminated as possible results. As nucleotides are dispensed, the number of candidates is successively decreased until only one or a few alternatives remain.
Sequencing system 100 may also include a data comparator 120. In one example, data comparator 120 may be an integral part of dispensation controller 112. In another example, data comparator 120 may be provided separate from dispensation controller 112. Data (e.g., registered and detected sequences) from data storage medium 116 and the contents of library 118 may be compared using data comparator 120. For example, data comparator 120 is used to retrieve the detected registered nucleic acid sequence stored in data storage medium 116 and then compares this information with possible results in library 118. Based on the returned information signal, certain candidate sequences or allele combinations in the library that do not match the registered and detected sequence (de novo sequence) can be eliminated because they are no longer possible sequences and, thus, can be neglected. Dispensation controller 112 is used to process a response signal and adapt the order of following dispensations in response to the comparison of the detected and registered sequence and the library of possible results. As nucleotides are dispensed, the amount of candidates is successively decreased.
Referring to
The method of
The method of
The method of
In response to determining that the dispensed nucleotide is not incorporated, the method of
At step 208, the method of
The method of
At step 310, the pyrosequencing reaction starts on operator command and a nucleotide is dispensed. Selection of a nucleotide to be dispensed may, for example, be based in part on non-sequence parameters (e.g., incidence of infection and/or diagnostic symptoms) and/or in part on frequency of a nucleotide in a database of possible candidate sequences. In one example, at least the first nucleotide to be dispensed is selected based on a query of a database(s) of non-sequence parameters (e.g., incidence of infection, diagnostic symptoms) and subsequent dispensations determined based on a comparison of the de novo sequence and the library of possible results (e.g., candidate sequences).
At step 312, a signal is detected by detector 114 and transmitted as a response signal to dispensation controller 112.
At decision step 314, dispensation controller 112 determines whether the response signal is unambiguous. If the response signal is not unambiguous, method 300 may return to step 310 to re-initiate the dispensation sequence. However, if the response signal is unambiguous, the response is interpreted as either a signal (nucleotide is incorporated) or lack of signal (nucleotide was not included). In some instances, signal processing may be required (i.e., measuring the program peak heights of detected signals) for incorporated nucleotides to accurately determine genotype. If the response signal is unambiguous, method 300 may proceed to step 316.
At step 316, exclusion of candidates is made. In this step, the de novo sequence is compared to the library of possible results. For example, data comparator 120 is used to retrieve the de novo sequence that is stored in data storage medium 116 and then compare this information with possible results in library 118. Certain candidate sequences in library 118 that do not match the registered and detected sequence (de novo sequence) can be eliminated because they are no longer possible sequences and, thus, can be neglected. The search space is reduced.
At decision step 318, it is determined whether a candidate has been uniquely determined. If a candidate has not been uniquely determined, method 300 may proceed to step 320 and the next dispensation is determined. However, if a candidate has been uniquely determined, method 300 may end.
At step 320, the next dispensation is determined. In this step, the remaining candidate sequences in the possible results of library 118 are queried and the next nucleotide to be dispensed is selected based on the on the most probable nucleotide for that position. The choice of dispensation is made to decrease the library of candidate sequences as much as possible. Method 300 returns to step 310 and the next nucleotide is dispensed. Method 300 may be repeated until a candidate has been uniquely determined or until the candidate library cannot be further decreased.
Any number of variations for method 300 is possible. For example, at a certain point in the hybrid pyrosequencing process where near 100% certainty of the candidate identity has been determined, method 300 may transition to a directed sequencing approach. In the directed sequencing approach, the candidate sequence is known and the exact nucleotides are dispensed in the known order to determine whether the specific sequence is present or not. Direct sequencing may be used to confirm the identity of the candidate.
In another example, at a certain point in the hybrid pyrosequencing process where all candidate sequences in the library of possible results have been excluded, method 300 may transition to a de novo sequencing approach. In the de novo sequencing approach, the nucleotides (A, G, C, and T) are added in a pre-determined order to determine the unknown sequence.
In yet another example, at a certain point in the hybrid pyrosequencing process where all candidate sequences in the library of possible results have been excluded, method 300 may query (e.g., via the Internet) another database and/or a larger database to continue with the hybrid pyrosequencing approach.
In yet another example, at a certain point in the hybrid pyrosequencing process multiple nucleotides (e.g., two or three nucleotides) may be dispensed simultaneously to potentially reduce the library of candidate sequences as much as possible process. For example, a database of candidate sequences may include four possibilities for the next two bases in the de novo sequence:
-
- (1) ATC
- (2) ATG
- (3) ACC
- (4) CTC
Two bases, A and T, may be dispensed together. If A and T are incorporated, as indicated by a double peak, candidate sequences (3) and (4) may be excluded from the search space. If only A is incorporated, as indicated by a single peak, candidate sequences (1), (2), and (4) may be excluded from the search space.
In yet another example, the order of nucleotide dispensation may be selected to distinguish similar organisms (sequences) in a sample. For example, a sample includes two organisms where at a certain position one sequence has AA and the other sequence has A. The sequencing program would show a 3× peak. To determine the distribution of the 3× signal for A, a database of candidate sequences may be queried for the most probable nucleotide to follow AA and the most probable nucleotide to follow A. If the most probable nucleotide to follow AA is G, and the most probable nucleotide to follow A is T, then G may be dispensed, followed by T. The expected result would be 2 1× peaks. Further sequencing would provide further confirmation.
ExamplesSelection of a nucleotide to be dispensed in a pyrosequencing reaction may be based in part on comparison of a de novo sequence with a database of non-sequence parameters and in part on frequency of a nucleotide in a database of possible candidate sequences. Non-sequence parameters may include, but are not limited to, selection criteria, such as incidence of infection and diagnostic symptoms. For example, a database of incidence of infection may include a plurality of infectious agents (e.g., bacterial, fungal and/or viral) associated with a certain probability of infection. The database may also include nucleic acid sequences of the organisms stored in the database (i.e., candidate sequences). A database of diagnostic symptoms may, for example, include a plurality of symptomatic information associated with a plurality of infectious agents (e.g., bacterial, fungal, and/or viral).
In one example, the selection of a particular nucleotide is based in part on incidence of infection data and in part on frequency of a nucleotide in a database of candidate sequences. For example, an incidence of infection database may include four bacteria species A, B, C and D with the following sequences and incidence of infection:
-
- A. CTGT—incidence is low
- B. CGGT—incidence is low
- C. CTTT—incidence is low
- D. TGCC—incidence is very high
An example of a method of selecting a nucleotide for dispensation based in part on incidence data and in part on frequency of a nucleotide in a database of candidate sequences may include, but is not limited to, the following steps.
In one step, T is dispensed based on the very high incidence of infection associated with bacteria D. If T is incorporated, the search space is limited to any sequences associated with bacteria D. If T is not incorporated, the search space is limited to any sequences associated with bacteria A, B, and C.
In another step, a database of candidate sequences is queried. In one example, a database of candidate sequences may be included as part of a database of incidence of infection. In another example, the database of candidate sequences may be a separate database. If T is incorporated in the step above, candidate sequences for bacteria D are examined. The choice of dispensation is made to decrease the library of candidate sequences as much as possible. For example, if three possible sequences are associated with bacteria D and of these three, two begin with T and one begins with C, C is dispensed. If T is not incorporated in the step above, candidate sequences for bacteria A, B, and C are examined.
In another example, the selection of one or more nucleotides is based solely on incidence of infection data to the extent that such data provides a useful selection criterion, and then when incidence of infection data is no longer useful, selection is based on nucleotide frequency in a database of candidate sequences.
In another example, the selection of a particular nucleotide is based in part on diagnostic data and in part on frequency of a nucleotide in a database of candidate sequences. In this example, a database of diagnostic symptoms that includes a plurality of symptomatic information associated with a plurality of infectious agents (e.g., bacterial, fungal, and/or viral) may be queried to initiate the pyrosequencing reaction.
In another example, the selection of a particular nucleotide is based in part on diagnostic data and incidence of infection data and in part on frequency of a nucleotide in a database of candidate sequences.
In yet another example, the selection process may include an algorithm that determines whether incidence data/diagnostic data or frequency in a database has the strongest predictive value, and then selects the nucleotide based on the strongest predictive value.
Droplet-Based PyrosequencingThe invention provides devices, systems and methods for hybrid pyrosequencing on a droplet actuator.
Electrode arrangement 300 includes multiple dispensing electrodes, which may, for example, be allocated as sample dispensing electrodes 310a and 310b for dispensing sample fluids (e.g., DNA immobilized on magnetically responsive beads); reagent dispensing electrodes 312, i.e., reagent dispensing electrodes 312a through 312e, for dispensing different reagent fluids (e.g., dATPas, dCTP, dGTP, dTTP, enzyme mix); wash buffer dispensing electrodes 314a and 314b for dispensing wash buffer fluids; and waste collection electrodes 316a and 316b for receiving spent reaction droplets. Sample dispensing electrodes 310, reagent dispensing electrodes 312, wash buffer dispensing electrodes 314, and waste collection electrodes 316 are interconnected through an arrangement, such as a path or array, of droplet operations electrodes 318. A path of droplet operations electrodes 318 extending from each dispensing and collection electrodes forms dedicated electrode lanes 320, i.e., dedicated electrode lanes 320a through 320i.
Electrode arrangement 300 may include a washing zone 322 and a reaction zone 324. A magnet 326 is located in close proximity to wash lane 322. Magnet 326 may be embedded within the deck that holds the droplet actuator when the droplet actuator is mounted on the instrument (not shown). Magnet 326 is positioned in a manner which ensures spatial immobilization of nucleic acid-attached beads during washing between the base additions. Mixing may be performed in reactor zone 324 away from magnet 326. The positioning of the wash dispensing electrodes 314 and waste collection electrodes 316 improves washing efficiency and reduces time spent in washing. A detection spot 328 is positioned in proximity of reactor zone 324.
A variety of pyrosequencing protocols may be executed using electrode arrangement 300 of the invention. An example of a three-enzyme pyrosequencing protocol is as follows. A PCR amplified DNA template hybridized to a sequencing primer may be coupled to magnetically responsive beads. A droplet of the beads suspended in wash buffer may be combined with a droplet of one of the four nucleotides mixed with APS and luciferin in wash buffer. A droplet containing all three enzymes (DNA polymerase, ATP sulfurylase and luciferase) may be combined with the bead and nucleotide-containing droplet. The resulting droplet may be mixed and transported to the detector location. Incorporation of the nucleotide may be detected as a luminescent signal proportional to the number of adjacent bases incorporated into the strand being synthesized, or as a background signal for a non-incorporated (mismatch) nucleotide. After the reaction is complete, the beads may be transported to the magnet and washed. Washing may be accomplished by addition and removal of wash buffer while retaining substantially all beads in the droplet. This entire sequence constitutes one full pyrosequencing cycle which may be repeated multiple times with the sequence of nucleotide additions determined in real-time.
In a specific example, a PCR amplified DNA template hybridized to a sequencing primer may be coupled to 2.8 μm diameter magnetically responsive beads. A 2×(800) nL droplet of the beads suspended in wash buffer may be dispensed and combined with a 1×(400 mL) droplet of one of the four nucleotides mixed with APS and luciferin in wash buffer. Selection of a nucleotide to be dispensed may, for example, be based in part on non-sequence parameters (e.g., incidence of infection and/or diagnostic symptoms) and/or in part on frequency of a nucleotide in a database of possible candidate sequences. In one example, at least the first nucleotide to be dispensed is selected based on a query of a database(s) of non-sequence parameters (e.g., incidence of infection, diagnostic symptoms) and subsequent dispensations determined based on a comparison of the de novo sequence and the library of possible results (e.g., candidate sequences). A 1×(400 mL) droplet containing all three enzymes (DNA polymerase, ATP sulfurylase and luciferase) may be combined with the beads and nucleotides resulting in a 4×(1600 mL) reaction volume. The 4× droplet may be mixed and transported to the detector location. Incorporation of the nucleotide may be detected as a luminescent signal proportional to the number of adjacent bases incorporated into the strand being synthesized, or as a background signal for a non-incorporated (mismatch) nucleotide. After the reaction is complete the beads may be transported to the magnet and washed by addition and removal of wash buffer finally resulting in the 1600 mL of reaction mix being replaced by 800 mL of fresh wash buffer while essentially all of the beads may be retained in the droplet. This entire sequence constituted one full pyrosequencing cycle which may be repeated multiple times with the sequence of nucleotide additions determined in real-time as described in reference to
The nucleic acid sequencing systems and methods of the invention are useful in a variety of settings including medical diagnostics. Rapid and accurate diagnosis of infectious disease is crucial both for the effective management of disease in individual patients and for ameliorating the public health problems of multi-drug resistant pathogens and community acquired infections.
In one embodiment, the systems and methods of the invention may be used to rapidly and efficiently identify and type human immunodeficiency (HIV) virus. One of the obstacles to effective treatment of HIV is its high genetic variability that is associated with resistance to antiretroviral therapies. Rapid identification of HIV and accurate subtyping of the virus is crucial for effective management of the disease. HIV subtyping may, for example, be performed using reverse transcriptase-polymerase chain reaction (RT-PCR) amplification of viral RNA and hybrid pyrosequencing. Selection of a nucleotide to be dispensed in a pyrosequencing reaction to subtype HIV may be based in part on comparison of a de novo sequence with a database of non-sequence parameters and in part on frequency of a nucleotide in a database of possible candidate sequences (i.e., HIV sequences). The database of non-sequence parameters may, for example, be a database of incidence of infection of HIV viral subtypes. The database of non-sequence parameters may be queried to select the next nucleotide to be dispensed to the extent that such data provides a useful selection criterion, and then when non-sequence parameter data is no longer useful, selection is based on nucleotide frequency in a database of candidate viral sequences.
In another embodiment, the systems and methods of the invention may be used to rapidly and efficiently identify and type methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a significant cause of healthcare- and community-associated infections, and its prevalence continues to increase. Currently, increasing numbers of community-acquired MRSA (CA-MRSA) strains are appearing that are able to cause severe infections in otherwise healthy people. High-level resistance to methicillin is caused by the mecA gene. The mecA regulon (mecA, mec1, and mecR1) is carried by a mobile genetic element designated staphylococcal cassette chromosome mec (SCCmec). SCCmec also includes the ccr gene complex and J regions (junkyard, J1, J2, and J3). Variations in the J regions may be used for defining SCCmec subtypes. MRSA typing may, for example, be performed using PCR amplification of bacterial DNA and hybrid pyrosequencing. In one example, selection of at least a first nucleotide to be dispensed in a pyrosequencing reaction to type MRSA may be based on a database of incidence of infection of MRSA types (non-sequence parameters). The database of non-sequence parameters may be queried to select the next nucleotide to be dispensed to the extent that such data provides a useful selection criterion, and then when non-sequence parameter data is no longer useful, selection is based on nucleotide frequency in a database of candidate MRSA sequences.
In yet another embodiment, the systems and methods of the invention may be used to rapidly and efficiently identify and type influenza A viruses. Influenza A viruses circulate worldwide and cause annual epidemics of human respiratory illness. Influenza A viruses are classified by subtype on the basis of the two main surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Different subtypes (e.g., H1N1 and H3N2) may be in circulation among human populations at different times. Influenza A viruses are further characterized into strains. Because influenza viruses are dynamic and constantly evolving, new strains continually appear. Rapid and accurate subtyping of the influenza A virus is important for effective management of the flu and timely development of appropriate anti-flu vaccines. Genotyping influenza A viruses may be based on polymorphisms in HA and/or NA coding regions or internal viral gene sequences. In one example, influenza A subtyping maybe performed using RT-PCR amplification of one or more internal gene sequences (e.g., NS, M, NP, PA, PB1, or PB2 genes) and hybrid pyrosequencing. Selection of at least a first nucleotide to be dispensed in a pyrosequencing reaction to subtype influenza A may be based on a database of incidence of infection of influenza A types (non-sequence parameter data). The database of incidence of infection of influenza A types may be queried to select the next nucleotide to be dispensed to the extent that such data provides a useful selection criterion, and then when non-sequence parameter data is no longer useful, selection is based on nucleotide frequency in a database of candidate influenza A sequences.
In yet another embodiment, the systems and methods of the invention may be used to rapidly and efficiently determine the sequences of known and unknown organisms (e.g., infectious agents) in complex environmental samples (e.g., food, water, air). An identification strategy may, for example, be based on the premise that sequencing the conserved ancient elements of the replicative machinery, such as a 1,500 base sequence of the 165 and 28S ribosomal DNA (rDNA) sequences, may be used to identify most bacterial and fungal pathogens, respectively. Sequencing of the variable regions of the 165 and 28S rDNA is widely accepted as the most robust and versatile method for identification of microbes in a complex environment where there are mixtures of organisms. The sequences that flank the variable regions of the 16S rDNA sequences in bacteria and 28S rDNA in fungi are highly conserved and may be used to amplify the variable regions of the sequences from all organisms, both known and unknown. These sequences show a great degree of homology in related organisms and may be used to make taxonomic identification. In one example, genomic DNA is isolated from a complex mixture of organisms in an environmental sample, such as a water sample. The genomic DNA is amplified using specific primers that flank the 16s (bacterial) and 28s rDNA (fungal) variable sequences. Selection of at least a first nucleotide to be dispensed in a pyrosequencing reaction to identify the organisms in the sample may, for example, be based on a database of incidence of contamination that includes a plurality of infectious agents (e.g., bacterial and fungal) typically associated with a sample source (e.g., a water sample). The database of incidence of contamination may be queried to select the next nucleotide to be dispensed to the extent that such data provides a useful selection criterion, and then when incidence of contamination data is no longer useful, selection is based on nucleotide frequency in a database of candidate bacterial and fungal sequences. If at a certain point in the hybrid pyrosequencing process where all candidate sequences in the databases of candidate bacterial and fungal sequences have been excluded, hybrid pyrosequencing may transition to a de novo sequencing approach. In the de novo sequencing approach, the nucleotides (A, G, C, and T) are added in a pre-determined order to determine the unknown sequence.
SystemsIt will be appreciated that various aspects of the invention may be embodied as a method, system, computer readable medium, and/or computer program product. Aspects of the invention may take the form of hardware embodiments, software embodiments (including firmware, resident software, micro-code, etc.), or embodiments combining software and hardware aspects that may all generally be referred to herein as a “circuit,” “module” or “system.” Furthermore, the methods of the invention may take the form of a computer program product on a computer-usable storage medium having computer-usable program code embodied in the medium.
Any suitable computer useable medium may be utilized for software aspects of the invention. The computer-usable or computer-readable medium may be, for example but not limited to, an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, device, or propagation medium. The computer readable medium may include transitory and/or non-transitory embodiments. More specific examples (a non-exhaustive list) of the computer-readable medium would include some or all of the following: an electrical connection having one or more wires, a portable computer diskette, a hard disk, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical fiber, a portable compact disc read-only memory (CD-ROM), an optical storage device, a transmission medium such as those supporting the Internet or an intranet, or a magnetic storage device. Note that the computer-usable or computer-readable medium could even be paper or another suitable medium upon which the program is printed, as the program can be electronically captured, via, for instance, optical scanning of the paper or other medium, then compiled, interpreted, or otherwise processed in a suitable manner, if necessary, and then stored in a computer memory. In the context of this document, a computer-usable or computer-readable medium may be any medium that can contain, store, communicate, propagate, or transport the program for use by or in connection with the instruction execution system, apparatus, or device.
Program code for carrying out operations of the invention may be written in an object oriented programming language such as Java, Smalltalk, C++ or the like. However, the program code for carrying out operations of the invention may also be written in conventional procedural programming languages, such as the “C” programming language or similar programming languages. The program code may be executed by a processor, application specific integrated circuit (ASIC), or other component that executes the program code. The program code may be simply referred to as a software application that is stored in memory (such as the computer readable medium discussed above). The program code may cause the processor (or any processor-controlled device) to produce a graphical user interface (“GUI”). The graphical user interface may be visually produced on a display device, yet the graphical user interface may also have audible features. The program code, however, may operate in any processor-controlled device, such as a computer, server, personal digital assistant, phone, television, or any processor-controlled device utilizing the processor and/or a digital signal processor.
The program code may locally and/or remotely execute. The program code, for example, may be entirely or partially stored in local memory of the processor-controlled device. The program code, however, may also be at least partially remotely stored, accessed, and downloaded to the processor-controlled device. A user's computer, for example, may entirely execute the program code or only partly execute the program code. The program code may be a stand-alone software package that is at least partly on the user's computer and/or partly executed on a remote computer or entirely on a remote computer or server. In the latter scenario, the remote computer may be connected to the user's computer through a communications network.
The invention may be applied regardless of networking environment. The communications network may be a cable network operating in the radio-frequency domain and/or the Internet Protocol (IP) domain. The communications network, however, may also include a distributed computing network, such as the Internet (sometimes alternatively known as the “World Wide Web”), an intranet, a local-area network (LAN), and/or a wide-area network (WAN). The communications network may include coaxial cables, copper wires, fiber optic lines, and/or hybrid-coaxial lines. The communications network may even include wireless portions utilizing any portion of the electromagnetic spectrum and any signaling standard (such as the IEEE 802 family of standards, GSM/CDMA/TDMA or any cellular standard, and/or the ISM band). The communications network may even include powerline portions, in which signals are communicated via electrical wiring. The invention may be applied to any wireless/wireline communications network, regardless of physical componentry, physical configuration, or communications standard(s).
Certain aspects of invention are described with reference to various methods and method steps. It will be understood that each method step can be implemented by the program code and/or by machine instructions. The program code and/or the machine instructions may create means for implementing the functions/acts specified in the methods.
The program code may also be stored in a computer-readable memory that can direct the processor, computer, or other programmable data processing apparatus to function in a particular manner, such that the program code stored in the computer-readable memory produce or transform an article of manufacture including instruction means which implement various aspects of the method steps.
The program code may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed to produce a processor/computer implemented process such that the program code provides steps for implementing various functions/acts specified in the methods of the invention.
CONCLUDING REMARKSThe foregoing detailed description of embodiments refers to the accompanying drawings, which illustrate specific embodiments of the invention. Other embodiments having different structures and operations do not depart from the scope of the invention. The term “the invention” or the like is used with reference to certain specific examples of the many alternative aspects or embodiments of the applicants' invention set forth in this specification, and neither its use nor its absence is intended to limit the scope of the applicants' invention or the scope of the claims. This specification is divided into sections for the convenience of the reader only. Headings should not be construed as limiting of the scope of the invention. The definitions are intended as a part of the description of the invention. It will be understood that various details of the invention may be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.
Claims
1-20. (canceled)
21. A system for identifying a nucleic acid sequence in a sample by hybrid pyrosequencing, the system comprising at least one controller configured to:
- (a) select a nucleotide to be dispensed to a sample comprising a primed DNA template and reagents sufficient for sequencing-by-synthesis of a de novo nucleic acid sequence to be identified, wherein the selection is based on a query of a database of non-sequence parameters and/or a comparison of the de novo sequence to a library of candidate sequences, further wherein the query of the database of non-sequence parameters comprises using an algorithm to determine whether the non-sequence parameters comprising incidence of infection and organism type or diagnostic symptoms and organism type, or frequency of the nucleotide in the library of candidate sequences has the strongest predictive value, and selecting the nucleotide based on the strongest predictive value;
- (b) control a dispenser to dispense the selected nucleotide to the sample;
- (c) control a detector to detect a response signal to the dispensation;
- (d) determine whether the dispensed nucleotide was incorporated or not incorporated;
- (e) repeat the select, dispense, detect, and determine functions in response to determining that the dispensed nucleotide was not incorporated;
- (f) compare the de novo sequence to the library of candidate sequences and
- (g) exclude candidate sequences that do not match the de novo sequence in response to determining that the dispensed nucleotide was incorporated; and
- (h) repeat the select, dispense, detect, determine, compare, and exclude functions until the de novo sequence is uniquely identified, wherein a sequence and/or nonsequence parameter database is queried during each reaction cycle.
22. The system of claim 21, further comprising a droplet actuator, wherein the at least one controller is configured to:
- (a) control the dispenser to dispense: (i) a first droplet comprising the primed DNA template immobilized on a bead; (ii) a second droplet comprising the selected nucleotide and detection reagents; and (iii) a third droplet comprising enzyme reagents; and
- (b) cause the droplet actuator to: (i) combine the first, second, and third droplets; (ii) transport the combined droplet to a detector location; and (iii) transport the droplets to a washing location for wash of the beads prior to returning to the dispense function.
23. The system of claim 22, wherein the detection reagents comprise ammonium persulfate and luciferin and the enzyme reagents comprise DNA polymerase, adenosine 5′ phosphosulfate, and luciferase.
24. The system of claim 22, wherein the bead is a magnetically responsive bead.
25. The system of claim 21, wherein identification of the nucleic acid sequence in the sample identifies one or more organisms in the sample.
26. The system of claim 25, wherein the organism is a bacteria, virus, or fungi.
27. The system of claim 21, wherein identification of the nucleic acid sequence in the sample rules out one or more organisms in the sample.
28. The system of claim 21, wherein identification of the nucleic acid sequence in the sample determines the nucleotide sequence of an unknown organism in the sample.
29. The system of claim 21, wherein the sample is a biological sample or an environmental sample.
30. The system of claim 21, wherein the nucleic acid sequence is a human immunodeficiency virus (HIV) sequence, a methicillin-resistant Staphylococcus aureus (MRSA) sequence, an influenza A sequence, or a 16S or 28S ribosomal DNA sequence of a known or an unknown organism.
31. The system of claim 21, wherein the database of non-sequence parameters comprises one or more of source of the sample, incidence of infection and organism type, or diagnostic symptoms and organism type.
32. (canceled)
33. The system of claim 21, wherein the at least one controller is configured to select a first nucleotide to be dispensed based in part on the query of a database of non-sequence parameters and in part on frequency of the nucleotide in the library of candidate sequences.
34. The system of claim 21, wherein the at least one controller is configured to select the nucleotide to be dispensed, subsequent to a first nucleotide to be dispensed, based on the comparison of the de novo sequence to the library of candidate sequences to select a most probable nucleotide for that position and to decrease the library of candidate sequences.
35. The system of claim 21, wherein the at least one controller is configured to transition to a directed sequencing approach wherein the de novo sequence is uniquely identified to near 100% certainty, and wherein the at least one controller is configured to dispense the nucleotide to the sample in an order dictated by the de novo sequence uniquely identified to near 100% certainty.
36. The system of claim 21, wherein the at least one controller is configured to transition to a de novo sequencing approach in response to all the candidate sequences in the library of candidate sequences being excluded, and wherein the at least one controller is configured to dispense the nucleotides A, G, C, and T to the sample in a predetermined order to identify the nucleotide sequence.
37. The system of claim 21, wherein the at least one controller is configured to query an additional database of candidate sequences in response to all the candidate sequences in the library of candidate sequences being excluded.
38. The system of claim 21, wherein the at least one controller is configured to control the dispenser to dispense multiple nucleotides simultaneously to reduce the library of candidate sequences.
39. The system of claim 38, wherein multiple nucleotides are 2 or 3 nucleotides.
40. The system of claim 21, and wherein the at least one controller is configured to distinguish between a first similar sequence and a second similar sequence in the library of candidate sequences based on a determination of the most probable nucleotide to follow in each of the first similar sequence and the second similar sequence.
41. A computer program product for identifying a nucleic acid sequence in a sample by hybrid pyrosequencing, the computer program comprising a computer readable storage medium having computer readable program code embodied therewith, the computer readable program code comprising:
- (a) computer readable program code configured to select a nucleotide to be dispensed to a sample comprising a primed DNA template and reagents sufficient for sequencing-by-synthesis of a de novo nucleic acid sequence to be identified, wherein the selection is based on a query of a database of non-sequence parameters and/or a comparison of the de novo sequence to a library of candidate sequences, further wherein the query of the database of non-sequence parameters comprises using an algorithm to determine whether the non-sequence parameters comprising incidence of infection and organism type or diagnostic symptoms and organism type, or frequency of the nucleotide in the library of candidate sequences has the strongest predictive value, and selecting the nucleotide based on the strongest predictive value;
- (b) computer readable program code configured to control a dispenser to dispense the selected nucleotide to the sample;
- (c) computer readable program code configured to receive signal data that is responsive to the dispensation;
- (d) computer readable program code configured to determine whether the dispensed nucleotide was incorporated or not incorporated;
- (e) computer readable program code configured to repeat the select, control, receive, and determine functions in response to determining that the dispensed nucleotide was not incorporated;
- (f) computer readable program code configured to compare the de novo sequence to the library of candidate sequences, and to exclude candidate sequences that do not match the de novo sequence in response to determining that the dispensed nucleotide was incorporated; and
- (g) computer readable program code configured to repeat the select, control, receive, determine, compare, and exclude functions until the de novo sequence is uniquely identified, wherein a sequence and/or nonsequence parameter database is queried during each reaction cycle.
Type: Application
Filed: Nov 11, 2014
Publication Date: Mar 5, 2015
Applicant: ADVANCED LIQUID LOGIC, INC. (San Diego, CA)
Inventors: Allen E. Eckhardt (San Diego, CA), Jonathan Benton (Apex, NC), Deborah Boles (Cary, NC)
Application Number: 14/538,379
International Classification: C12N 15/10 (20060101); C12Q 1/70 (20060101); C12Q 1/68 (20060101);
